SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Husemann Y, Creigi BJ, Schubert, et al. Systemic spread is an early step in breast cancer. Cancer Cell. 2008; 13: 58-68.
  • 2
    Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005; 353: 793-802.
  • 3
    Harris L, Fritsche H, Mennel R, et al. American Society Of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25: 5287-5312.
  • 4
    Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351: 781-791.
  • 5
    Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006; 12: 4218-4224.
  • 6
    Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006; 12: 6403-6409.
  • 7
    Diel IJ, Kaufmann M, Costa SD, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst. 1966; 88: 1652-1658.
  • 8
    Gerber B, Krause A, Muller H, et al. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol. 2001; 19: 960-971.
  • 9
    Braun S, Cevatli BS, Assemi C, et al. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol. 2001; 192: 1468-1475.
  • 10
    Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer. N Engl J Med. 2000; 342: 525-533.
  • 11
    Ignatiadis M, Xenidis N, Perraki M, et al. Different prognostic value of cytokeratin 19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early stage breast cancer. J Clin Oncol. 2007; 25: 5194-5201.
  • 12
    Ignatiadis M, Kallergi G, Ntoulia M, et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A and HER2 in early breast cancer. Clin Cancer Res. 2008; 14: 2593-2600.
  • 13
    Xenidis N, Perraki M, Kafousi M, et al. Predictive and prognostic value of peripheral blood cytokeratin 19 mRNA positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol. 2006; 24: 3756-3762.
  • 14
    Ntoulia M, Stathopoulou A, Ignatiadis M, et al. Detection of mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood cancer with rested RT-PCR. Clin Biochem. 2006; 39: 879-887.
  • 15
    Lang JE, Mosalpuria K, Cristofanilli, et al. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat. 2008; 113: 501-507.
  • 16
    Rack BK, Schindlbeck C, Hofmann S, et al. Circulating tumor cells (CTCs) in peripheral blood of primary breast cancer patients [abstract]. Proc Am Soc Clin Oncol. 2007; 25: 10595. Abstract 10595.